Glucagen Hypokit (Glucagon)

Glucagen Hypokit is indicated for the treatment of severe hypoglycemia when rapid glucose elevation is required.

• Emergency treatment of insulin‑induced hypoglycemia in adults.
• Management of hypoglycemia in children when oral glucose is not feasible.
• Use in patients with adrenal insufficiency experiencing hypoglycemic episodes.
• Administration by trained personnel in hospital, ambulance, or home settings.

Glucagen Hypokit may cause a range of adverse reactions; most are mild and transient, while rare events can be serious.

Common

• Nausea or vomiting.
• Flushing or warmth at the injection site.
• Headache.
• Transient rise in blood pressure.
• Dizziness.
• Tremor.
• Local pain or bruising at injection site.

Serious

• Allergic reactions such as rash, urticaria, or anaphylaxis.
• Severe hyperglycemia requiring medical intervention.
• Cardiovascular events such as arrhythmia in susceptible patients.
• Hypersensitivity reactions including angioedema.

When using Glucagen Hypokit, clinicians should consider several precautions to ensure safe and effective treatment of hypoglycemia.

• Verify the diagnosis of severe hypoglycemia before administration.
• Use only when intravenous glucose is unavailable or delayed.
• Avoid repeated dosing within a short interval; monitor blood glucose closely.
• Adjust dose in patients with known glucagon antibody presence.
• Exercise caution in patients with pheochromocytoma or insulinoma.
• Store the kit according to manufacturer instructions, protecting from light and extreme temperatures.

Glucagen Hypokit can interact with certain medications or clinical conditions; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use of beta‑blockers that may mask typical glucagon side effects.
• Administration with other agents that cause hyperglycemia, such as high‑dose corticosteroids, without monitoring.
• Concomitant use of somatostatin analogues, which may blunt glucagon’s effect.

Use with caution

• Patients receiving oral hypoglycemic agents; monitor for rebound hypoglycemia after glucagon effect wanes.
• Individuals on monoamine oxidase inhibitors; observe for potential cardiovascular effects.
• Use in patients with known hypersensitivity to glucagon or kit components.
• Patients with renal or hepatic impairment; dose may need adjustment.
• Patients with cardiovascular disease; monitor hemodynamic response.